Efficacy of a new formulation of a daily lctp dose of tacrolimus (ENVARSUS®) to prevent diabetes post renal transplant in patients at risk: a controlled randomized open pilot study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

28 Jun 2022 Results (n=57; between Junuary 2017 and January 2022) assessing safety of tacrolimus once-daily dose LCTP (Envarsus) formulation to prevent post kidney transplant diabetes in at-risk patients, presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022.
24 May 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com